Brokerage morning meeting highlights: Now is the right time for AI healthcare layout.

In today's Brokerage morning meeting, Sinolink proposed that the layout of AI in healthcare is timely; HTSC expressed a bullish outlook on the product upgrades and commercial breakthroughs of AI applications in China by 2025; China Securities Co.,Ltd. believes that the turning point in the IDC Industry is approaching, and a new cycle is expected to begin.

cls.cn19:26 ET

Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.

In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.

Zhitong FinanceFeb 13 22:11 ET

[Hong Kong Stock Connect] SHANDONG XINHUA (00719) has received registration approval from the National Medical Products Administration for empagliflozin tablets, which are suitable for the treatment of type 2 diabetes.

Jinwu Financial News | SHANDONG XINHUA (00719) announced that the company recently received the Drug Registration Certificate for Empagliflozin Tablets (10mg) approved and issued by the National Medical Products Administration. This product meets the relevant requirements for drug registration and is approved for registration. Empagliflozin Tablets are indicated for the treatment of type 2 diabetes; they are used in adult patients with symptomatic chronic heart failure to reduce the risk of hospitalization due to heart failure.

Jingwu Financial NewsJan 21 04:12 ET

SHANDONG XINHUA (00719.HK): The empagliflozin tablets (10mg) have obtained the pharmaceutical registration certificate.

On January 21, Gelonghui reported that SHANDONG XINHUA (00719.HK) announced that the company recently received the Drug Registration Certificate for Empagliflozin Tablets (10mg) (hereinafter referred to as "the product") issued by the National Medical Products Administration. This product meets the relevant requirements for drug registration and is approved for registration. In June 2023, Shandong Xinhua Pharmaceutical submitted the registration application for the market approval of Empagliflozin Tablets (10mg) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration and received acceptance. The Drug Registration Certificate was obtained in January 2025, with the review conclusion being approved for registration. Empagliflozin is developed by Boehringer Ingelheim.

Gelonghui FinanceJan 21 03:34 ET

Express News | Shandong Xinhua Pharmaceutical - Empagliflozin Tablets (10Mg) Obtained Drug Registration Certificate by China Nmpa

ReutersJan 21 03:31 ET

SHANDONG XINHUA (00719) has received the "Pharmaceutical Supplement Application Approval Notice" for Rosuvastatin Calcium Tablets (20mg; 10mg).

SHANDONG XINHUA (00719) announced that recently, the company received approval from the National Medical Products Administration for the issuance of Ruishu...

Zhitong FinanceJan 21 03:31 ET